MOTS-c and BPC-157: the evidence so far

If you have seen MOTS-c and BPC-157 mentioned in the same breath on a peptide forum, you are not alone. The two get grouped together because both are injectable peptides people reach for around training, recovery and joint pain, and because both landed on the agenda when a US Food and Drug Administration advisory committee met on 23 and 24 July 2026 to consider whether compounding pharmacies should be allowed to prepare them. The committee voted narrowly in favour of recommending both^[5]. That is not the same as either peptide being approved as a medicine, and the honest summary of the human evidence for both is short: there is very little of it.

What MOTS-c is, and what the evidence shows

MOTS-c is a mitochondrial-derived peptide, a 16-amino-acid chain encoded inside the mitochondrial genome rather than the cell nucleus. Its interest to athletes comes from exercise physiology. Levels of MOTS-c rise in human muscle and blood during and after exercise, and in animal work the peptide behaves like a metabolic regulator that changes how cells handle glucose and energy. In a controlled rat study, twelve weeks of MOTS-c injections alongside aerobic exercise improved myocardial mechanical efficiency and cardiac systolic function compared with exercise alone^[1]. That is a real finding, but it is a finding in rats. The US Anti-Doping Agency describes MOTS-c as an experimental peptide with no FDA approval, and notes that while exercise raises MOTS-c in people, the performance claims rest on animal models rather than completed human trials^[4]. There is no published human trial showing that injecting MOTS-c preserves muscle, speeds recovery, or does anything a reader on a cut is hoping for.

What BPC-157 is, and where the human data stands

BPC-157, short for Body Protection Compound 157, is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. Our BPC-157 page covers it in depth. The rodent literature is large and often positive: rat studies report faster healing of cut tendons and ligaments, and protection against gut lesions. A 2019 review in Cell Tissue Research reported consistently positive healing effects across injury types, then added the caveat that matters, which is that most of that work has been done in small rodent models and efficacy in humans has not been confirmed in clinical trials^[2]. There is no published phase 2 or phase 3 randomised trial of BPC-157 for tendon, joint or back injury. The US Department of Defense Operation Supplement Safety programme is blunt about the status: BPC-157 is not a dietary ingredient, it is an unapproved drug, and there is little to no reliable scientific evidence for its safety or effectiveness in humans^[3].

The FDA vote is not an approval

It is worth being precise about what happened in July 2026, because the forum framing of the FDA loosening up on peptides is easy to misread. The body that met was the Pharmacy Compounding Advisory Committee, and its job is to advise the FDA on which bulk substances compounding pharmacies may lawfully prepare under section 503A. It voted to recommend BPC-157, TB-500 and MOTS-c for that list, but the votes are not binding, FDA scientists reportedly opposed the move, and the agency makes the final decision through a separate rulemaking process^[5]. None of this grants either peptide a marketing authorisation. Neither MOTS-c nor BPC-157 is an approved medicine in the US, the EU, or the UK today, and a favourable compounding recommendation does not change that. Our coverage tracks the country-by-country position, including for TB-500 and Semax, other peptides weighed at the same meeting.

What we don't yet know

For both peptides, the list of open questions is long. We do not have a human dose range established by trial, so any protocol quoted online is extrapolated from animal work rather than validated in people. We do not know the long-term safety of repeated dosing, the interactions with other drugs, or the effect in anyone with an existing endocrine or oncological condition. Both peptides sit on the World Anti-Doping Agency Prohibited List, so they are banned in and out of competition for tested athletes: MOTS-c as a metabolic modulator, BPC-157 under the non-approved substances category^[4]. And because the supply is grey market, independent testing routinely finds vials that are underdosed, mislabelled, or contain the wrong molecule, which means the contents may not even match the label.

If you are dealing with knee and back pain after years of physical work, the appeal of a recovery peptide is obvious. The honest position is that the human evidence for MOTS-c and BPC-157 does not yet support the claims made for them, and the regulatory status is unsettled. Anyone weighing these up should talk it through with a clinician who knows their history rather than lean on a forum protocol. Our regulation coverage for BPC-157 sets out what is known, what is not, and where the peptide stands in your country.